Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CytoDyn has named current director Kenneth Van Ness as the new president and CEO of the company.
Subscribe to our email newsletter
Ness will succeed Allen Allen, the current chairman, president and CEO.
During the past 25 years Ness has held various C level positions in both domestic, public, private and international companies, in a variety of industries.
Ness said he is honored to become president and CEO and to help move CytoDyn forward in its evolution and development.
"CytoDyn will continue to refine and develop a collaborative effort to move our primary, one-of-a-kind drug, Cytolin, to the completion of its necessary clinical trials," Ness said.
CytoDyn founder and chairman Allen said Ness will have his full support, and he is confident that Ness will deliver a new era of growth for the company’s shareholders.